Does Epoetin Beta Still Have a Place in Peginterferon Alpha-2a Plus Ribavirin Treatment Strategies for Chronic Hepatitis C?-Reference-Cited by-同舟云学术

Does Epoetin Beta Still Have a Place in Peginterferon Alpha-2a Plus Ribavirin Treatment Strategies for Chronic Hepatitis C?

Published:2016-03 Issue:3 Volume:36 Page:204-214
ISSN:1079-9907
Container-title:Journal of Interferon & Cytokine Research
language:en
Short-container-title:Journal of Interferon & Cytokine Research

Author:

Veillon Pascal¹²,Fouchard-Hubert Isabelle²³,Larrey Dominique⁴,Dao Manh Thông⁵,D'alteroche Louis⁶,Boyer-Darrigand Nathalie⁷,Picard Nicolas⁸,Le Guillou-Guillemette Hélène¹²,Saulnier Patrick⁹,Ducancelle Alexandra¹²,Loustaud-Ratti Véronique¹⁰,Lunel-Fabiani Françoise¹²

Affiliation:

1. Department of Virology, University Hospital of Angers, Angers, France.

2. HIFIH Research Unit, Faculty of Medicine, UPRES 3859, SFR 4208, University of Angers, Angers, France.

3. Department of Hepatology and Gastroenterology, University Hospital of Angers, Angers, France.

4. Department of Hepatology and Transplantation, University Hospital of Montpellier, Montpellier, France.

5. Gastroenterology and Nutrition, University Hospital of Caen, Caen, France.

6. Department of Hepatology and Gastroenterology, University Hospital of Tours, Chambray-les-Tours, France.

7. Department of Hepatology, Physiopathology and Treatment of Viral Hepatitis, Hospital of Beaujon, Clichy, France.

8. INSERM UMR-850, Department of Pharmacology, Toxicology and Pharmacovigilance, University Hospital of Limoges, Limoges, France.

9. Micro and Nanomedecines biomimetics, INSERM UMRS 1066, University of Angers, Angers, France.

10. Department of Hepatology and Gastroenterology, University Hospital of Limoges, INSERM UMR 1092, Limoges, France.

Publisher

Mary Ann Liebert Inc

Subject

Virology,Cell Biology,Immunology

Link

http://www.liebertpub.com/doi/pdf/10.1089/jir.2015.0131

Reference49 articles.

1. Epoetin alfa maintains ribavirin dose in HCV-infected patients: a prospective, double-blind, randomized controlled study1 1The other PROACTIVE Study Group investigators included the following: Vijayan Balan, M.D., Mayo Clinic Scottsdale, Scottsdale, Arizona; Norbert Bräu, M.D., Bronx VA Medical Center, Bronx, New York; Robert Brown, M.D., M.P.H., NY Presbyterian Medical Center, New York, New York; William Carey, M.D., Cleveland Clinic Foundation, Cleveland, Ohio; Andrea Duchini, M.D., Baylor College of Medicine, Houston, Texas; Greg Everson, M.D., University of Colorado Health Sciences Center, Denver, Colorado; Michael Fried, M.D., University of North Carolina, Chapel Hill, North Carolina; Robert Gish, M.D., California Pacific Medical Center, San Francisco, California; Ira Jacobson, M.D., Weill Medical College of Cornell University, New York, New York; John W. King, LSU Health Sciences Center, Shreveport, LA; Raymond Koff, M.D., University of Massachusetts Memorial Health Care, Worcester, Massachusetts; William Lee, M.D., University of Texas Southwestern Medical Center, Dallas, Texas; Mark A. Levstik, M.D., The University of Tennessee, Memphis, Tennessee; John G. McHutchison, M.D., Scripps Clinic, La Jolla, California; Marion Peters, M.D., University of California San Francisco, San Francisco, California; Kenneth Sherman, M.D., Ph.D., University of Cincinnati College of Medicine, Cincinnati, Ohio; Coleman Smith, M.D., Minnesota Clinical Research Center, St. Paul, MN; Ronald Wasserman, M.D., Hepatitis Resource Center, Walnut Creek, California.

2. Impact of erythropoietin on sustained virological response to peginterferon and ribavirin therapy for HCV infection: a systematic review and meta-analysis

3. Predictors of response of U.S. veterans to treatment for the hepatitis C virus

4. Clinical trial: exposure to ribavirin predicts EVR and SVR in patients with HCV genotype 1 infection treated with peginterferon alfa-2a plus ribavirin

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Efficiency and Safety of an Early Dose Adjustment of Ribavirin in Patients Infected With Hepatitis C Underexposed to the Drug and Treated With Peginterferon Ribavirin;Therapeutic Drug Monitoring;2016-12